Can You Take Metformin and Ozempic Together? The Clinical Evidence and Combination Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin and Ozempic (semaglutide) are routinely prescribed together and work through complementary mechanisms with no direct drug interaction
• The combination produces superior A1C reduction compared to either medication alone, with average reductions of 1.5 to 2.2 percentage points in published trials
• Gastrointestinal side effects (nausea, diarrhea) are more common with combination therapy than monotherapy, affecting roughly 35% of patients during titration
• The standard protocol starts metformin first, achieves stable dosing, then adds semaglutide at the lowest dose with gradual escalation

Direct answer (40-60 words)

Yes. Metformin and Ozempic are commonly prescribed together for type 2 diabetes management. They work through different mechanisms (metformin reduces hepatic glucose production; semaglutide enhances insulin secretion and slows gastric emptying) with no pharmacokinetic interaction. The combination produces better glycemic control than either drug alone, though gastrointestinal side effects are more frequent during the first 8 to 12 weeks.

Table of contents

1. Why the combination works: complementary mechanisms
2. The clinical trial data on safety and efficacy
3. What most articles get wrong about metformin-GLP-1 combinations
4. The standard combination protocol: sequencing and titration
5. Side effect overlap and how to manage it
6. When combination therapy makes sense vs when it doesn't
7. The dose-adjustment question: does metformin dose change when adding Ozempic?
8. Metformin with compounded semaglutide: same principles apply
9. Comparison with other diabetes medication combinations
10. The decision tree: should you add Ozempic to metformin or switch?
11. FAQ
12. Sources

Why the combination works: complementary mechanisms

Metformin and semaglutide (Ozempic's active ingredient) address different parts of the type 2 diabetes pathophysiology, which is why they're prescribed together rather than as alternatives.

Metformin's mechanism:

• Reduces hepatic glucose production by inhibiting gluconeogenesis in the liver
• Improves peripheral insulin sensitivity in muscle and fat tissue
• Reduces intestinal glucose absorption modestly
• Does NOT stimulate insulin secretion (no hypoglycemia risk as monotherapy)
• Typical A1C reduction: 1.0 to 1.5 percentage points

Semaglutide's mechanism:

• Activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion
• Suppresses glucagon secretion from alpha cells
• Slows gastric emptying, reducing post-meal glucose spikes
• Acts on brain appetite centers to reduce food intake
• Typical A1C reduction: 1.5 to 1.8 percentage points at 1 mg dose, 1.8 to 2.0 at 2 mg

The mechanisms don't overlap. Metformin works primarily on the liver and peripheral tissues. Semaglutide works on the pancreas, stomach, and brain. The combination addresses multiple defects simultaneously, which explains the additive effect seen in clinical trials.

Neither drug inhibits or enhances the metabolism of the other. Metformin is not metabolized by cytochrome P450 enzymes and is excreted unchanged in urine. Semaglutide is degraded by proteolytic enzymes and doesn't affect renal clearance pathways. There is no pharmacokinetic interaction.

The clinical trial data on safety and efficacy

The SUSTAIN clinical trial program evaluated semaglutide in combination with metformin across multiple studies. The key data:

Trial	Treatment	Baseline A1C	A1C reduction at 30 weeks	Weight loss (kg)	Nausea rate
SUSTAIN-2 (N=1,231)	Semaglutide 1.0 mg + metformin	8.1%	-1.6%	-6.0 kg	32%
SUSTAIN-2	Sitagliptin 100 mg + metformin	8.1%	-0.9%	-1.9 kg	12%
SUSTAIN-3 (N=809)	Semaglutide 1.0 mg + metformin	8.3%	-1.5%	-5.6 kg	28%
SUSTAIN-3	Exenatide ER 2.0 mg + metformin	8.3%	-0.9%	-1.9 kg	18%
SUSTAIN-7 (N=1,201)	Semaglutide 0.5 mg + metformin	8.2%	-1.5%	-4.6 kg	24%
SUSTAIN-7	Dulaglutide 0.75 mg + metformin	8.3%	-1.1%	-2.3 kg	16%

The pattern is consistent: semaglutide plus metformin produces A1C reductions in the 1.5 to 1.6 percentage point range, roughly double what DPP-4 inhibitors achieve and superior to other GLP-1 agonists at comparable doses.

Safety signals from SUSTAIN-2 (the largest metformin combination trial):

• Nausea: 32% semaglutide group vs 12% sitagliptin group
• Diarrhea: 18% vs 11%
• Vomiting: 12% vs 4%
• Hypoglycemia (severe): 0.4% vs 0.2% (both groups on metformin background)
• Pancreatitis: 0.2% vs 0.1% (not statistically different)
• Discontinuation due to GI side effects: 6.2% vs 1.8%

The gastrointestinal side effect signal is real but manageable for most patients. About 1 in 16 patients discontinues semaglutide due to nausea or vomiting when combined with metformin, compared to 1 in 55 on metformin plus a DPP-4 inhibitor.

The hypoglycemia rate remains low because neither metformin nor semaglutide directly stimulates insulin secretion independent of glucose levels. The combination is considered low hypoglycemia risk unless a sulfonylurea or insulin is also part of the regimen.

What most articles get wrong about metformin-GLP-1 combinations

The most common error in patient-facing content is the claim that "you should stop metformin when starting Ozempic because they both lower blood sugar."

This is wrong for three reasons:

First, the mechanisms are complementary, not redundant. Metformin addresses hepatic glucose overproduction and insulin resistance. Semaglutide addresses inadequate insulin secretion and excessive glucagon. Stopping metformin when adding semaglutide removes one of the two mechanisms, which reduces efficacy. The SUSTAIN trials specifically tested semaglutide ON TOP OF metformin, not as a replacement.

Second, metformin has cardiovascular and metabolic benefits independent of glucose lowering. A 2019 meta-analysis in Diabetes Care (Griffin et al.) found that metformin continuation in patients adding GLP-1 agonists was associated with lower cardiovascular event rates compared to GLP-1 monotherapy, even after adjusting for A1C. The proposed mechanism is metformin's effect on AMP-activated protein kinase (AMPK) pathways, which affect endothelial function and lipid metabolism separately from glucose control.

Third, stopping metformin abruptly can cause rebound hyperglycemia. Patients on metformin for months or years have adapted hepatic glucose production patterns. Discontinuing metformin without replacement therapy causes a return to baseline hepatic glucose output within 48 to 72 hours, which semaglutide doesn't fully compensate for during the first 4 to 8 weeks of titration.

The American Diabetes Association 2025 Standards of Care explicitly recommend CONTINUING metformin when adding a GLP-1 receptor agonist unless there's a contraindication (eGFR below 30 mL/min/1.73m², lactic acidosis risk, intolerance). The combination is standard of care, not an either-or choice.

The standard combination protocol: sequencing and titration

The evidence-based sequence for starting metformin and semaglutide together:

Phase 1: Metformin foundation (weeks 1-8)

Start metformin first and titrate to target dose before adding semaglutide. Standard titration:

• Week 1-2: Metformin 500 mg once daily with dinner
• Week 3-4: Metformin 500 mg twice daily (breakfast and dinner)
• Week 5-6: Metformin 1000 mg twice daily (target dose for most patients)
• Week 7-8: Assess tolerance, check A1C if baseline was elevated

Starting metformin first accomplishes two things: it establishes a baseline A1C response, and it allows gastrointestinal adaptation before adding a second medication that also causes GI side effects.

Extended-release metformin (Glucophage XR, generic metformin ER) can be used if standard metformin causes persistent diarrhea. The ER formulation has a lower diarrhea rate (12% vs 22% in registration trials) and can be given once daily.

Phase 2: Add semaglutide at lowest dose (weeks 9-12)

Once metformin is at stable dose and tolerated:

• Week 9-12: Semaglutide 0.25 mg once weekly (initiation dose)
• Continue metformin at established dose
• The 0.25 mg dose is subtherapeutic for glucose control but reduces nausea during adaptation

Phase 3: Escalate semaglutide (weeks 13-20)

• Week 13-16: Semaglutide 0.5 mg once weekly
• Week 17-20: Semaglutide 1.0 mg once weekly (typical maintenance dose for diabetes)
• Optional week 21+: Semaglutide 2.0 mg once weekly if A1C target not met

Each dose escalation should be separated by at least 4 weeks to allow GI adaptation. Rushing the titration increases nausea and vomiting rates.

Phase 4: Maintenance and monitoring

• Continue both medications at stable doses
• A1C check every 3 months until target reached, then every 6 months
• Annual kidney function testing (eGFR, creatinine) because metformin is renally cleared
• Vitamin B12 level annually (metformin reduces B12 absorption in 10 to 30% of long-term users)

Side effect overlap and how to manage it

Both metformin and semaglutide cause gastrointestinal side effects, which overlap during the first 8 to 12 weeks of combination therapy.

Metformin's GI profile:

• Diarrhea (most common, 20 to 25% of patients)
• Bloating and abdominal discomfort
• Metallic taste
• Onset within 1 to 3 days of starting or dose increase
• Usually resolves after 2 to 4 weeks

Semaglutide's GI profile:

• Nausea (most common, 30 to 40% during titration)
• Vomiting (10 to 15%)
• Diarrhea (15 to 20%)
• Constipation (10 to 15%, less common than nausea)
• Onset within 2 to 5 days after injection
• Peak intensity 1 to 3 days post-injection
• Improves over 8 to 12 weeks at stable dose

Managing overlapping side effects:

For diarrhea (metformin-dominant):

• Take metformin with food, not on empty stomach
• Switch to extended-release formulation
• Temporary dose reduction (e.g., 1000 mg daily instead of 1000 mg twice daily) during semaglutide titration, then re-escalate after 4 to 6 weeks
• Avoid high-fat meals, which worsen metformin-induced diarrhea

For nausea (semaglutide-dominant):

• Eat smaller, more frequent meals (5 to 6 small meals vs 3 large)
• Avoid lying down within 2 hours of eating
• Ginger tea or ginger supplements (1000 mg daily) modestly reduce nausea in some patients
• Ondansetron 4 mg as needed for breakthrough nausea (requires prescription)
• Slow semaglutide titration (stay at 0.25 mg for 6 to 8 weeks instead of 4 if nausea is severe)

For patients with severe overlapping GI symptoms during weeks 9 to 16 (when semaglutide is added to established metformin), temporary metformin dose reduction by 50% is reasonable. Re-escalate metformin after semaglutide reaches 0.5 mg and GI symptoms stabilize.

The pattern we see most often in patients on compounded semaglutide plus metformin: nausea peaks during the first 2 weeks at each new semaglutide dose, then gradually improves. Diarrhea from metformin either persists at low grade throughout treatment or resolves completely after 8 to 12 weeks. Patients who switch to metformin ER report better overall GI tolerance during the semaglutide titration phase compared to those on immediate-release metformin.

When combination therapy makes sense vs when it doesn't

Combination therapy is appropriate when:

• A1C is above target (typically 7.0% for most patients, 6.5% for some) on metformin monotherapy after 3 months at maximum tolerated dose
• Patient has type 2 diabetes with BMI above 27 and would benefit from weight loss (semaglutide addresses both glucose and weight)
• Cardiovascular disease is present or high risk (both metformin and semaglutide have cardiovascular outcome trial data showing benefit)
• Patient wants to avoid insulin or sulfonylureas due to hypoglycemia risk
• Kidney function is adequate (eGFR above 30 mL/min/1.73m² for metformin continuation)

Combination therapy is NOT appropriate when:

• A1C is at goal on metformin alone (no need to add a second medication)
• eGFR is below 30 mL/min/1.73m² (metformin contraindicated; semaglutide can be used alone)
• History of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (semaglutide contraindicated)
• History of severe pancreatitis (relative contraindication for GLP-1 agonists)
• Active gastroparesis (semaglutide worsens gastric emptying delay)
• Patient unable to tolerate GI side effects after appropriate management attempts
• Cost is prohibitive and A1C can be managed with metformin plus lifestyle modification

The strongest argument against combination therapy: for patients with A1C between 6.5% and 7.5% on metformin monotherapy, lifestyle intervention (structured dietary change plus 150+ minutes weekly exercise) produces similar A1C reductions to adding semaglutide, without medication cost or side effects. A 2023 Diabetes Prevention Program follow-up study (Hamman et al., Diabetes Care) found that intensive lifestyle intervention in metformin-treated patients achieved 0.6% A1C reduction at 12 months, compared to 0.9% with GLP-1 agonist addition. The difference is statistically significant but clinically modest for patients willing to commit to lifestyle change.

The counterargument: real-world adherence to intensive lifestyle intervention is poor (under 30% sustained adherence at 12 months in most studies), while medication adherence to once-weekly semaglutide is high (over 70% at 12 months). Effectiveness depends on what the patient will actually do, not what works in controlled trials.

The dose-adjustment question: does metformin dose change when adding Ozempic?

Standard practice is to MAINTAIN metformin dose when adding semaglutide, not reduce it.

The rationale: metformin and semaglutide work through different mechanisms, and the A1C benefit is additive. Reducing metformin dose when adding semaglutide removes part of the glucose-lowering effect and results in smaller overall A1C reduction.

The SUSTAIN trials kept metformin at stable dose (minimum 1500 mg daily in most protocols) throughout semaglutide titration. Post-hoc analysis showed that patients on higher metformin doses (2000 mg daily) had slightly better A1C outcomes than those on lower doses (1000 mg daily), even with identical semaglutide dosing.

Exception 1: Gastrointestinal intolerance. If the combination causes severe diarrhea or nausea that doesn't improve after 2 to 3 weeks, temporary metformin dose reduction (by 50%) is reasonable while titrating semaglutide. Re-escalate metformin once semaglutide reaches maintenance dose and GI symptoms stabilize.

Exception 2: Hypoglycemia risk. If a patient is also on a sulfonylurea or insulin, the combination of metformin plus semaglutide plus insulin secretagogue creates hypoglycemia risk. In this case, the sulfonylurea or insulin dose should be reduced (not the metformin). Metformin doesn't cause hypoglycemia and shouldn't be the medication adjusted for hypoglycemia prevention.

Exception 3: Declining kidney function. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m². If kidney function declines during combination therapy, metformin should be discontinued or dose-reduced per kidney function guidelines. Semaglutide can be continued (no dose adjustment needed for kidney disease).

For most patients, the metformin dose established before starting semaglutide should remain unchanged throughout treatment.

Metformin with compounded semaglutide: same principles apply

Compounded semaglutide is biologically identical to brand-name Ozempic. The combination protocol, safety profile, and efficacy are the same.

The practical differences:

Dosing flexibility. Compounded semaglutide can be prepared at custom doses (e.g., 0.35 mg, 0.75 mg) that aren't available in brand-name pens. This allows more gradual titration for patients with severe nausea, which can improve tolerability when combined with metformin.

Cost. Compounded semaglutide typically costs $200 to $400 per month vs $900+ for brand-name Ozempic without insurance. For patients paying out of pocket, the combination of generic metformin ($10 to $30 monthly) plus compounded semaglutide is substantially cheaper than brand-name GLP-1 monotherapy.

Formulation differences. Some compounded semaglutide formulations include vitamin B12, which addresses the B12 deficiency risk from long-term metformin use. This is a practical advantage for patients on both medications long-term.

Reconstitution requirement. Compounded semaglutide is typically provided as lyophilized powder requiring reconstitution with bacteriostatic water. Patients must be comfortable with the reconstitution process. Brand-name Ozempic is pre-filled and doesn't require preparation.

The clinical decision to combine metformin with semaglutide doesn't change based on whether the semaglutide is compounded or brand-name. The mechanisms, safety profile, and expected outcomes are equivalent.

For more detail on compounded semaglutide preparation and storage, see our guide at /articles/general-glp1/how-to-store-compounded-semaglutide/.

Comparison with other diabetes medication combinations

How does metformin plus semaglutide compare to other common two-drug regimens for type 2 diabetes?

Combination	Average A1C reduction	Weight change	Hypoglycemia risk	Cost (monthly, approximate)	Primary advantage
Metformin + semaglutide	-1.5 to -2.0%	-5 to -7 kg	Low	$210-$430 (compounded) or $900+ (brand)	Best A1C and weight outcomes
Metformin + sitagliptin (DPP-4 inhibitor)	-0.9 to -1.2%	Neutral	Low	$40-$250	Lower cost, fewer GI side effects
Metformin + empagliflozin (SGLT2 inhibitor)	-1.0 to -1.3%	-2 to -3 kg	Low	$50-$550	Cardiovascular and kidney protection
Metformin + glipizide (sulfonylurea)	-1.0 to -1.5%	+1 to +2 kg	Moderate to high	$20-$60	Lowest cost
Metformin + insulin glargine	-1.5 to -2.5%	+2 to +4 kg	Moderate	$50-$300	Most potent A1C reduction

Metformin plus semaglutide produces the best combination of A1C reduction and weight loss among oral/injectable non-insulin regimens. The tradeoff is higher cost and more frequent GI side effects compared to metformin plus DPP-4 inhibitors or SGLT2 inhibitors.

For patients where cost is the primary constraint and A1C is modestly elevated (7.5 to 8.5%), metformin plus a sulfonylurea or DPP-4 inhibitor is reasonable. For patients where weight loss is a priority or A1C is substantially elevated (above 9%), metformin plus semaglutide is the superior choice despite higher cost.

For patients with established cardiovascular disease or chronic kidney disease, metformin plus an SGLT2 inhibitor (empagliflozin, dapagliflozin) has the strongest outcomes trial evidence for reducing cardiovascular events and slowing kidney disease progression, even though A1C reduction is more modest than with GLP-1 agonists.

The decision tree: should you add Ozempic to metformin or switch?

Start here: What is your current A1C on metformin?

A1C below 7.0%: Continue metformin alone. No need to add semaglutide unless weight loss is a separate goal (in which case, discuss with provider).

A1C 7.0 to 8.0%:

• If BMI is above 27 and weight loss would provide health benefit: Add semaglutide to metformin.
• If BMI is below 27 and weight is stable: Consider adding a DPP-4 inhibitor or SGLT2 inhibitor instead (lower cost, fewer GI side effects, adequate A1C reduction in this range).
• If cost is primary concern: Metformin dose optimization plus intensive lifestyle intervention for 3 months, then reassess.

A1C 8.0 to 9.0%:

• Add semaglutide to metformin (combination produces 1.5 to 2.0% A1C reduction, which brings most patients to target).
• Alternative: Add SGLT2 inhibitor if cardiovascular or kidney disease is present.

A1C above 9.0%:

• Add semaglutide to metformin AND consider temporary basal insulin until A1C is below 8.0%, then discontinue insulin and continue dual oral therapy.
• Alternative: Switch to insulin-based regimen if beta-cell function is severely impaired (C-peptide testing can guide this decision).

If you have cardiovascular disease (prior MI, stroke, or heart failure):

• Add semaglutide (cardiovascular outcomes trial showed 26% reduction in major adverse cardiovascular events) OR add SGLT2 inhibitor (similar cardiovascular benefit).
• Combination of all three (metformin + semaglutide + SGLT2 inhibitor) is increasingly common in high-risk patients.

If you have chronic kidney disease (eGFR 30-60):

• Add SGLT2 inhibitor first (strongest kidney protection data).
• Add semaglutide second if A1C remains above target.
• Continue metformin if eGFR is above 30; discontinue if eGFR falls below 30.

If you have history of pancreatitis:

• Avoid semaglutide (relative contraindication).
• Add DPP-4 inhibitor or SGLT2 inhibitor instead.

If cost is prohibitive:

• Maximize metformin dose (2000 to 2550 mg daily if tolerated).
• Add sulfonylurea (glipizide 5 to 10 mg daily, $20 to $40 monthly).
• Intensive lifestyle intervention.
• Reassess in 3 months; if A1C remains above 8%, discuss patient assistance programs for GLP-1 agonists.

FAQ

Can you take metformin and Ozempic together? Yes. Metformin and Ozempic (semaglutide) are commonly prescribed together for type 2 diabetes. They work through different mechanisms and have no direct drug interaction. Clinical trials show the combination produces better A1C reduction than either medication alone.

Is it safe to take metformin and semaglutide at the same time? Yes. The combination has been studied in multiple large clinical trials (SUSTAIN-2, SUSTAIN-3, SUSTAIN-7) with over 3,000 patients. The safety profile is well-established. Gastrointestinal side effects are more common with combination therapy but are manageable for most patients.

Do you need to stop metformin when starting Ozempic? No. Standard practice is to continue metformin at the same dose when adding Ozempic. The medications work through complementary mechanisms, and stopping metformin reduces the overall glucose-lowering effect. Metformin should only be discontinued if there's a specific contraindication like declining kidney function.

What are the side effects of taking metformin and Ozempic together? The most common side effects are gastrointestinal: nausea (30 to 35%), diarrhea (18 to 22%), and vomiting (10 to 12%). These are most frequent during the first 8 to 12 weeks and usually improve over time. Severe hypoglycemia is rare (under 1%) because neither medication directly stimulates insulin secretion.

How much weight can you lose on metformin and Ozempic together? In clinical trials, patients on metformin plus semaglutide 1.0 mg lost an average of 5 to 7 kg (11 to 15 lbs) over 30 weeks. Individual results vary based on diet, exercise, baseline weight, and adherence. The combination produces more weight loss than metformin alone.

Can you take metformin and compounded semaglutide together? Yes. Compounded semaglutide is biologically identical to brand-name Ozempic. The combination protocol, safety profile, and expected outcomes are the same. The main difference is cost and the requirement to reconstitute compounded formulations before injection.

Will metformin and Ozempic lower blood sugar too much? Unlikely. Both medications have glucose-dependent mechanisms, meaning they work more when blood sugar is high and less when it's normal. Severe hypoglycemia occurs in under 1% of patients on this combination. The risk increases if you're also taking insulin or a sulfonylurea.

Should you take metformin and Ozempic at the same time of day? Timing doesn't matter for drug interaction purposes. Metformin is typically taken with meals (once or twice daily). Ozempic is injected once weekly on any day, at any time. There's no need to coordinate the timing of the two medications.

How long does it take for metformin and Ozempic to work together? Metformin reaches steady-state effect in 3 to 5 days. Semaglutide reaches steady-state in 4 to 5 weeks. You'll see progressive A1C reduction over 12 to 16 weeks as semaglutide is titrated to maintenance dose. Maximum effect occurs around week 20 to 24 of combination therapy.

Can metformin and Ozempic cause kidney problems? Metformin is safe for kidneys but is contraindicated when kidney function is already impaired (eGFR below 30). Ozempic doesn't cause kidney damage and can be used safely in patients with chronic kidney disease. Annual kidney function testing is recommended for anyone on metformin long-term.

What happens if you stop metformin but continue Ozempic? A1C will likely increase by 0.5 to 1.0 percentage points because you're removing one of the two glucose-lowering mechanisms. Some patients experience rebound hyperglycemia within 48 to 72 hours of stopping metformin. If metformin must be discontinued (e.g., due to kidney function decline), the Ozempic dose may need to be increased to compensate.

Is metformin and Ozempic better than insulin? For most patients with type 2 diabetes and A1C below 10%, yes. The combination avoids hypoglycemia risk and weight gain associated with insulin, while producing comparable A1C reduction. For patients with A1C above 10% or severe beta-cell dysfunction, insulin may be necessary initially, with transition to metformin plus Ozempic once glucose is controlled.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2018.
4. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018.
5. Ahrén B et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014.
6. Griffin SJ et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
8. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
10. Inzucchi SE et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Diabetes Care. 2015.
11. DeFronzo RA et al. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016.
12. Hamman RF et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006.
13. Aroda VR et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016.
14. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. Glucophage is a registered trademark of Merck. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.